respiratory
ILD

Pirfenidone may improve results for patients with non-IPF fibrotic ILDs: RELIEF

Pirfenidone yielded improved outcome over placebo in a trial of patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). However, though the results were significant, the trial was terminated early due to slow recruitment, leaving the use of this agent in non-IPF fibrotic ILDs still in question. “Expert groups independent of ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic